Shots:

• The collaboration offers a compassionate access program to make the combination therapy of Veyonda & 7Lu-PSMA available to the patients suffering from mCRPC- being treated with theranostics in Australia
• The combination regimen is currently being evaluated in clinical studies in patients with advanced mCRPC- demonstrating improvement in response rate with mOS (17.1mos.) and a reduction in pain following disease progression
• Veyonda (bid for 10 days) is a suppository dosage form of idronoxil and inhibitor of S1P and enhances the effect of Lutetium-PSMA (Lu-PSMA) in men with advanced PC

Click here ­to­ read full press release/ article | Ref: Noxopharm | Image: Noxopharm